Opus Genetics, Inc.

Opus Genetics, Inc. reported a net loss of $49.6 million for fiscal year 2025, an improvement from a net loss of $57.5 million in the prior year. The company generated $14.2 million in license and collaborations revenue, primarily from its Viatris License Agreement, compared to $11.0 million in 2024. Total operating expenses were $52.8 million, down from $73.1 million in 2024, which included a $28.0 million charge for acquired in-process research and development related to the Opus Acquisition. The net loss per share was $0.80, improved from $2.15 in the prior year. The company ended the year with $45.1 million in cash and cash equivalents, bolstered by $50.0 million in net cash provided by financing activities, including equity offerings. The forward-looking significance centers on advancing its clinical-stage gene therapy pipeline, including OPGx-LCA5 and OPGx-BEST1, with key clinical data readouts and regulatory interactions planned.

Key Takeaways